Pear Therapeutics has struck a deal to license voice biomarkers to try to improve treatment for patients with illnesses ranging from Alzheimer’s to insomnia and substance use disorder.
In a flurry of announcements Tuesday, the Boston-based company said it is licensing voice biomarker technology from Winterlight Labs Inc., a startup from Toronto that uses machine learning to pinpoint vocal changes associated with the onset of dementia and psychiatric diseases.
The deal marks one of the first attempts to demonstrate the clinical value of voice biomarkers to detect early signs of an illness, an eye-catching area of research that has yet to prove its worth in the lives of real patients.
About the Author Reprints
